| Literature DB >> 24136773 |
Roberto Sasdelli Neto, Cesar Higa Nomura, Ana Carolina Sandoval Macedo, Danilo Perussi Bianco, Fernando Uliana Kay, Gilberto Szarf, Gustavo Borges da Silva Teles, Hamilton Shoji, Pedro Vieira Santana Netto, Rodrigo Bastos Duarte Passos, Rodrigo Caruso Chate, Walther Yoshiharu Ishikawa, João Paulo Bacellar Costa Lima, Marcelo Assis Rocha, Vinícius Neves Marcos, Bruna Bonaventura Failla, Marcelo Buarque de Gusmão Funari.
Abstract
Coronary computed tomography angiography (coronary CTA) is a powerful non-invasive imaging method to evaluate coronary artery disease. Nowadays, coronary CTA estimated effective radiation dose can be dramatically reduced using state-of-the-art scanners, such as 320-row detector CT (320-CT), without changing coronary CTA diagnostic accuracy. To optimize and further reduce the radiation dose, new iterative reconstruction algorithms were released recently by several CT manufacturers, and now they are used routinely in coronary CTA. This paper presents our first experience using coronary CTA with 320-CT and the Adaptive Iterative Dose Reduction 3D (AIDR-3D). In addition, we describe the current indications for coronary CTA in our practice as well as the acquisition standard protocols and protocols related to CT application for radiation dose reduction. In conclusion, coronary CTA radiation dose can be dramatically reduced following the "as low as reasonable achievable" principle by combination of exam indication and well-documented technics for radiation dose reduction, such as beta blockers, low-kV, and also the newest iterative dose reduction software as AIDR-3D.Entities:
Mesh:
Year: 2013 PMID: 24136773 PMCID: PMC4878605 DOI: 10.1590/s1679-45082013000300025
Source DB: PubMed Journal: Einstein (Sao Paulo) ISSN: 1679-4508
Indications for coronary computed tomographic angiography
| Indication | Clinical features | Score |
|---|---|---|
| Non-acute symptomatic patients | Interpretable electrocardiogram AND able to exercise | A-7 |
| Uninterpretable electrocardiogram OR unable to exercise | A-8 | |
| Acute (urgent presentation) symptomatic patients | Normal electrocardiogram and cardiac biomarkers | A-7 |
| Non-diagnostic electrocardiogram OR equivocal cardiac biomarkers | A-7 | |
| Acute chest pain of uncertain cause | U-6 | |
| Use of computed tomographic angiography in the setting of prior test results – prior electrocardiogram exercise testing | Normal electrocardiogram exercise test and continued symptoms | A-7 |
| Prior electrocardiogram exercise testing and Duke Treadmill Score - intermediate risk findings | A-7 | |
| Discordant electrocardiogram exercise and imaging results | A-8 | |
| Evaluation of computed tomographic calcium score >100 in symptomatic or between 100-400 | A-8 | |
| Risk assessment post-revascularization (percutaneous coronary intervention or coronary artery bypass grafting surgery) | Coronary artery bypass grafting surgery evaluation in symptomatic patients (ischemic equivalent) | A-8 |
| Asymptomatic; prior left main coronary stent with stent diameter ≥3mm | A-8 | |
| Evaluation of cardiac structure | Assessment of anomalies of coronary arterial and other thoracic arteriovenous vessels | A-9 |
| Assessment of complex adult congenital heart disease | A-8 | |
| Evaluation of ventricular morphology and systolic function | A-7 | |
| Evaluation of cardiac structure and function – evaluation of intra and extracardiac structures | Characterization of native or prosthetic cardiac valves (suspected dysfunction) | A-8 |
| Evaluation of cardiac mass (suspected tumor or thrombus) | A-8 | |
| Preoperative assessment | Prior biventricular pacemaker placement | A-8 |
| Prior cardiac surgery to assess coronary | A-8 |
Score 7 to 9: test is generally acceptable and is reasonable approach for the indication; score 4 to 6: test may be generally acceptable and may be a reasonable approach for the indication; score 1 to 3: test is not generally acceptable and is not a reasonable approach for the indication.
A: appropriate test for specific indication;
U: uncertain test for specific indication.
Institutional lowering heart rate protocols with orally and intravenously beta blockers
| HR (beats/minutes) | Beta blocker dose |
|---|---|
| <55 | None |
| 55<HR<60 | 5mg IV of metoprolol tartrate (Seloken®), if necessary |
| 60<HR<70 | 5-15 mg IV of metoprolol tartrate (Seloken®) 15 minutes before scan |
| 70<HR<80 | 40mg of propranolol hydrochloride (Inderal®) orally or metoprolol tartrate (Seloken®) 5-15 mg IV, 15-45 minutes before scan |
| 80<HR<90 | 100mg of metoprolol tartrate (Seloken®) orally or 40mg of propranolol hydrochloride (Inderal®) orally at least 1 hour before the scan |
| HR>90 | 100mg of metoprolol tartrate (Seloken®) orally at least 1 hour before the scan |
IV: intravenous; HR: heart rate.
320-row computed tomographic scanner acquisition parameters for three different coronary computed tomographic angiography protocols
| Exam | Detectors/collimation/tube rotation speed | Kilovoltage (kV) | Current intensity (mA) | FOV (mm) | Range (mm) | Pitch | Wide Volume | Filter | RR interval phases | Dose modulation software | CM injection |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Prospective coronay computed tomographic | 320/0,5/0,35 | 80-135 | Sure Exposure 3D CTA Standard | (M) 220 | 120 | 0 | Off | Cardiac Stent (AIDR-Standard) | 70, 75 and 80% | Prosp CTA (Sure Cardio) | Flow: 4,5-5mL/s CM volume: 75mL |
| Coronary computed tomographic/revascularized pacient | 320/0,5/0,35 | 80-135 | Sure Exposure 3D CTA Standard | (M) 220 | 232 | 0 | On | Cardiac Stent (AIDR-Standard) | 70, 75 and 80% | Prosp CTA (Sure Cardio) | Flow: 4,5-5mL/s CM volume: 100mL |
| Aortic prothesis | 80/0,5/0,35 | 100 kV when BMI <30 | 1st sequence: Sure Exposure 3D CTA Standard | (M) 220 | — | 1st sequence: standard | Off | Body Standard and Lung | Angiographic: coronary, thoracic and abdominal aorta until iliac bifurcation | CTA/CFA continous (Sure Cardio) | Flow: 4,5-5mL/s CM volume is equal to 10 units plus the acquisition time |
| 120 kV when BMI >30 | 2nd sequence: Sure Exposure Low Dose | 2nd sequence |
Variable helical pitch allows division in acquisition parameters. Thoracic acquisition is electrocardiogram-triggered. Abdominal acquisition is performed without electrocardiogram trigger, which is automatically turned off allowing a single apnea examination and lowering contrast administration.
Sure Exposure 3D®, SureCardio® and AIDR-Standard® are trade registered marks and data was supplied by Toshiba Medical Systems (Tochigi-ken, Japan).
FOV: field of view; CM: contrast media; BMI: body mass index; CTA: coronary computed tomography angiography; CFA: cardiac function assessment.
Figure 1Comparison between two coronary computed tomographic angiography examinations of the same patient, the first without AIDR-3D (Figures A-C) and the second with AIDR-3D (Figures D-F). The noise is different on axial computed tomographic images (Figures A and D), but the curved-MIP (Figures B and E) and 3D volume-rendering (Figures C and F) reconstructions are similar. Estimated effective radiation dose from coronary computed tomography angiography only and full examination were respectively 6.6mSv and 8.8mSv (exam without AIDR-3D), and 1.97mSv and 3.9mSv (exam with AIDR-3D)
Figure 2Coronary computed tomographic angiography examination with AIDR-3D. Axial image (A), curved-MIP (B) and 3D volume-rendering (C) reconstructions. Estimated effective radiation dose from coronary computed tomographic angiography only and full examination were 0.43mSv and 1.02mSv, respectively